FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook. [PDF]
Moriyama H, Moriyama S, Yokota T.
europepmc +1 more source
Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation. [PDF]
Siddika A +5 more
europepmc +1 more source
The atomic structure of human dystrophin spectrin-like repeat 24. [PDF]
Streeter O +6 more
europepmc +1 more source
Genetic cardiomyopathy unmasked by pregnancy: X-linked dystrophinopathy presenting as peripartum cardiomyopathy-a case report. [PDF]
Bauer J +4 more
europepmc +1 more source
(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective. [PDF]
Remmel HL +3 more
europepmc +1 more source
Duchenne muscular dystrophy coexisting with Down syndrome or Turner syndrome: Two case reports. [PDF]
Pongsakornkullachart P +7 more
europepmc +1 more source
Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy. [PDF]
Lopez Perez MA, Weisleder NL.
europepmc +1 more source
Cytoplasmic region of beta-dystroglycan is essential for postsynaptic maturation and neuromuscular function in mice. [PDF]
Hord JM +9 more
europepmc +1 more source
U7snRNA-mediated skipping of intron-derived pseudoexons restores full-length <i>DMD</i> expression in patient-derived cell lines. [PDF]
Beljan JC +7 more
europepmc +1 more source

